Twist Bioscience Corporation and Ginkgo Bioworks announced on May 8, 2025, an updated collaboration renegotiated from a prior contract signed in 2022. The revised three-year, $15 million agreement ensures Ginkgo will continue as a customer, prepaying annually for Twist’s high-quality DNA products with preferential pricing and no required minimum purchase volume.
As credit against the 2022 agreement, Twist receives licenses and assignments for certain long DNA and other technology, as well as related reagents, to complement its existing DNA synthesis portfolio of products. This strategic acquisition strengthens Twist's position as a leader in the field of DNA synthesis.
Ginkgo retains the rights to practice the IP transferred to Twist, while Twist gains optionality to incorporate the long DNA technology on its own platform. This arrangement secures a valued customer relationship and enhances Twist's technological capabilities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.